文献速递MDS 与骨髓增殖性肿瘤

SIMPLIFY-1:莫美替尼对比芦可替尼在未接受JAK抑制剂治疗的骨髓纤维化患者中的III期随机试验

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
PubMed 文献 · J Clin Oncol · 2017-09-20

SIMPLIFY-1研究纳入432例未接受过JAK抑制剂的高危、中危-2或有症状的中危-1骨髓纤维化患者,随机接受24周莫美替尼200mg每日一次或芦可替尼20mg每日两次(或按说明书)治疗,主要终点为24周时脾体积缩小≥35%。莫美替尼组脾应答非劣于芦可替尼组(26.5% vs 29%,P=0.011),但症状应答未达到非劣效(28.4% vs 42.2%,P=0.98);莫美替尼组输血需求改善,但≥3级感染和周围神经病变发生率更高。

要点

  • 莫美替尼组24周脾体积缩小≥35%的患者比例为26.5%,芦可替尼组为29%,非劣效检验P=0.011。
  • 莫美替尼组总症状评分缩小≥50%的患者比例为28.4%,低于芦可替尼组的42.2%,未达到非劣效(P=0.98)。
  • 莫美替尼组输血率、输血独立性和输血依赖性均改善(名义P≤0.019),但≥3级感染(7% vs 3%)和周围神经病变(10% vs 5%)更常见。

核心结论

  • 在未接受过JAK抑制剂的骨髓纤维化患者中,莫美替尼治疗24周在脾应答方面非劣于芦可替尼,但在症状应答方面未达到非劣效。
  • 莫美替尼治疗与输血需求降低相关。

研究设计与样本

  • III期随机试验,纳入432例高危、中危-2或有症状的中危-1骨髓纤维化且未接受过JAK抑制剂的患者。
  • 患者随机接受24周莫美替尼200mg每日一次或芦可替尼20mg每日两次(或按说明书)治疗,之后所有患者可接受开放标签莫美替尼。

主要发现

  • 24周时脾体积缩小≥35%的患者比例:莫美替尼组26.5%,芦可替尼组29%(非劣效,P=0.011)。
  • 总症状评分缩小≥50%的患者比例:莫美替尼组28.4%,芦可替尼组42.2%(未达到非劣效,P=0.98)。
  • 莫美替尼组输血率、输血独立性和输血依赖性均改善(名义P≤0.019)。
  • 两组最常见的≥3级血液学异常均为血小板减少和贫血。
  • ≥3级感染发生率:莫美替尼组7%,芦可替尼组3%;治疗期间出现的周围神经病变发生率:莫美替尼组10%(均为≤2级),芦可替尼组5%(均为≤3级)。

关键数值与推荐

  • 主要终点为24周时脾体积缩小≥35%。
  • 次要终点包括症状应答率和红细胞输注需求的影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose We evaluated the efficacy and safety of momelotinib, a potent and selective Janus kinase 1 and 2 inhibitor (JAKi), compared with ruxolitinib, in JAKi-naïve patients with myelofibrosis. Patients and Methods Patients (N = 432) with high risk or intermediate-2 risk or symptomatic intermediate-1 risk myelofibrosis were randomly assigned to receive 24 weeks of treatment with momelotinib 200 mg once daily or ruxolitinib 20 mg twice a day (or per label), after which all patients could receive open-label momelotinib. The primary end point was a ≥ 35% reduction in spleen volume at 24 weeks of therapy. Secondary end points were rates of symptom response and effects on RBC transfusion requirements. Results A ≥ 35% reduction in spleen volume at week 24 was achieved by a similar proportion of patients in both treatment arms: 26.5% of the momelotinib group and 29% of the ruxolitinib group (noninferior; P = .011). A ≥ 50% reduction in the total symptom score was observed in 28.4% and 42.2% of patients who received momelotinib and ruxolitinib, respectively, indicating that noninferiority was not met ( P = .98). Transfusion rate, transfusion independence, and transfusion dependence were improved with momelotinib (all with nominal P ≤ .019). The most common grade ≥ 3 hematologic abnormalities in either group were thrombocytopenia and anemia. Grade ≥ 3 infections occurred in 7% of patients who received momelotinib and 3% of patients who received ruxolitinib. Treatment-emergent peripheral neuropathy occurred in 10% of patients who received momelotinib (all grade ≤ 2) and 5% of patients who received ruxolitinib (all grade ≤ 3). Conclusion In JAKi-naïve patients with myelofibrosis, 24 weeks of momelotinib treatment was noninferior to ruxolitinib for spleen response but not for symptom response. Momelotinib treatment was associated with a reduced transfusion requirement.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. J Clin Oncol. 2017. PMID: 28930494. doi:10.1200/JCO.2017.73.4418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。